Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
EPS (Diluted) · Q2 FY2026 · quarter ended Jun 2026
EPS (Diluted) remains negative
Q2 FY2026 EPS (Diluted) was -$0.08, compared with -$0.27 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.54.
Context
- EPS (Diluted) increased in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 5 analysts of -$0.07 (+92.2%) for the fiscal year ending Dec 2026, a step up from the +13.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$0.08-213.7% QoQ
- Last fiscal yearDec 2025
- -$0.91+13.3% YoY
- LTMJun 2026
- -$0.54+60.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +70.4% | +64.1% | -6.3 pp |
| 1 year | +13.3% | +92.2% | +78.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.91) USD
- Year-over-year change
- +13.3%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.91) | +13.3% |
| FY2024 | 2024-12-31 | (1.05) | -16.7% |
| FY2023 | 2023-12-31 | (0.90) | -153.9% |
| FY2022 | 2022-12-31 | 1.67 | +7.1% |
| FY2021 | 2021-12-31 | 1.56 | — |
EPS (Diluted) vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 EPS (Diluted) of -$0.54 is the 8th highest of the 9 companies compared; the peer median is -$0.23.
- Its year-over-year change of +60.6% is the 5th highest of 9, against a peer median of +54.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $8.25 | -29.7% | — | |
| LTM Sep 2026 | $1.1 | +124.5% | -13.0% | |
| LTM Jun 2026 | $0.73 | +812.5% | -35.7% | |
| LTM Mar 2026 | -$0.22 | +8.5% | — | |
| LTM Mar 2026 | -$0.25 | +28.4% | — | |
| LTM Aug 2026 | -$0.25 | +94.7% | — | |
| LTM Mar 2026 | -$0.43 | +81.2% | — | |
| LTM Jun 2026 | -$0.54 | +60.6% | — | |
| LTM Sep 2026 | -$3.62 | -178.5% | — | |
| Peer median (excluding MRVI) | -$0.23 | +54.8% | -24.4% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 799.24M | 883M | 288.95M | 259.19M | 185.74M |
| Cost of Revenue | 140.56M | 168.96M | 148.74M | 150.88M | 152.35M |
| Gross Profit | 658.68M | 714.04M | 140.2M | 108.31M | 33.39M |
| Gross Margin | 82.4% | 80.9% | 48.5% | 41.8% | 18.0% |
| Research & Development | 15.22M | 18.37M | 17.28M | 19.22M | 23.33M |
| Selling, General & Admin | 100.06M | 129.26M | 151.39M | 161.77M | 171.47M |
| Operating Expenses | 104.03M | 139.83M | 171.85M | 343.93M | 40.13M |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| EBITDA | 585.78M | 609.99M | 712.41M | (156.92M) | (147.51M) |
| EBITDA Margin | 73.3% | 69.1% | 246.6% | -60.5% | -79.4% |
| Operating Income | 554.65M | 574.22M | (31.65M) | (235.62M) | (6.74M) |
| Operating Margin | 69.4% | 65.0% | -11.0% | -90.9% | -3.6% |
| Interest Income | 0 | 2.34M | 27.73M | 27.4M | 23.95M |
| Interest Expense | 30.26M | 20.41M | 45.89M | 47.7M | 26.99M |
| Other Income / Expenses | (23.88M) | (22.74M) | 649.38M | (25.87M) | (228.24M) |
| Income Before Tax | 530.77M | 551.47M | 617.74M | (261.48M) | (234.97M) |
| Pre-Tax Margin | 66.4% | 62.5% | 213.8% | -100.9% | -126.5% |
| Income Tax Expense | 61.52M | 60.81M | 756.11M | (1.86M) | (4.21M) |
| Net Income | 182.04M | 220.21M | (119.03M) | (144.85M) | (130.77M) |
| Net Margin | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
| EPS (Basic) | 1.59 | 1.67 | (0.90) | (1.05) | (0.91) |
| EPS (Diluted) | 1.56 | 1.67 | (0.90) | (1.05) | (0.91) |
| Weighted Avg Shares | 114.79M | 131.54M | 131.92M | 137.91M | 145.07M |
| Weighted Avg Shares (Diluted) | 121.97M | 131.7M | 131.92M | 137.91M | 145.07M |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.